Aachen, Germany – On Monday, September 21, 2026, Grünenthal, a global leader in pain management and research, announced their agreement with Bayer AG to acquire Stivarga®, an established oral treatment for certain advanced cancers, for up to €375 million. This latest step is part of Grünenthal’s strategic plan to acquire established medicines that fulfill clear medical needs…
No responses yet